Digestive Diseases and Sciences

, Volume 45, Issue 1, pp 63–67 | Cite as

Factors that May Affect Treatment Outcome of Triple Helicobacter pylori Eradication Therapy with Omeprazole, Amoxicillin, and Clarithromycin

  • Sotirios D. Georgopoulos
  • Spiros D. Ladas
  • Stylianos Karatapanis
  • Andreas Mentis
  • Charis Spiliadi
  • Vasilios Artikis
  • Sotirios A. Raptis
Article

Abstract

Factors affecting Helicobacter pylori eradication rate with omeprazole (OME), clarithromycin (CL), and amoxicillin (AMO) have not been extensively studied. We have investigated the effect of age, sex, smoking, ulcer disease, compliance with therapy, H. pylori colonization density, degree and activity of antral gastritis, the coexistence of corpus gastritis, and the presence of lymphoid follicles on H. pylori eradication rate. We studied 80 consecutive H. pylori-positive patients, with duodenal ulcer (N = 35) or nonulcer dyspepsia (N = 45) treated with OME 20 mg, CL 500 mg, and AMO 1 g, each given twice daily for 10 days. H. pylori was eradicated in 71/80 (88.8%, 95% CI 82–96%) patients. The regimen failed to eradicate the only strain (1.8%, 95% CI 0–5.2%) that was clarithromycin resistant. Multivariate discriminant analysis showed that two histological variables (Wilks λ = 0.74, χ2 = 23.41, df = 2, P < 0.001), absence of lymphoid follicles in routine gastric biopsies (F = 13.63, P < 0.001) and coexistence of antral and body gastritis (F = 13.68, P < 0.001), significantly increased H. pylori eradication rate. No other factor examined predicted H. pylori eradication with this regimen. Our data suggest that body gastritis is a positive and presence of lymphoid follicles in routine gastric biopsies is a negative predictive factor of treatment outcome with the omeprazole, clarithromycin, and amoxicillin regime.

Helicobacter pylori follicular gastritis omeprazole clarithromycin amoxicillin Helicobacter pylori gastritis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Warren JR, Marshall B: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1:1273-1275, 1983PubMedGoogle Scholar
  2. 2.
    Graham DY: Campylobacter pylori and peptic ulcer disease. Gastroenterology 96:615-625, 1989PubMedGoogle Scholar
  3. 3.
    Rauws EA, Tytgat GNJ: Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335:1233-1235, 1990PubMedGoogle Scholar
  4. 4.
    Rokkas T, Karameris A, Mavrogeorgis A, Rallis E, Giannikos N: Helicobacter pylori eradication reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 41:1-4, 1995PubMedGoogle Scholar
  5. 5.
    Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, Fedorak R, Bazzoli F, Hentchel E, Mora P, Archimandritis A: Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. Aliment Pharmacol Ther 11:943-952, 1997PubMedGoogle Scholar
  6. 6.
    Lind T, Veldhuyzen van Zanten SJO, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antibiotics. The MACH 1 Study. Helicobacter 1:138-144, 1996PubMedGoogle Scholar
  7. 7.
    Laine L, Estrada R, Trujilo M, Fukanaga K, Neil G: Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 10:1029-1033, 1996PubMedGoogle Scholar
  8. 8.
    Laine L, Suchower L, Frantz J, Connors A, Neil G: Twicedaily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: Results of three multicenter, double-blind, United States trials. Am J Gastroenterol 93:2106-2112, 1998PubMedGoogle Scholar
  9. 9.
    Price AB: The Sydney system: Histological division. J Gastroenterol Hepatol 6:209-222, 1991PubMedGoogle Scholar
  10. 10.
    Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575-577, 1993PubMedGoogle Scholar
  11. 11.
    Tzelepi E, Mentis AF, Spiliadis C, Tzouvelekis LS: Antibiotic susceptibility and plasmid content of Helicobacter pylori strains isolated in Greece. Int J Exp Clin Chemother 4:111-113, 1991Google Scholar
  12. 12.
    The European Helicobacter pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41:8-13, 1997Google Scholar
  13. 13.
    Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM: Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 102:493-496, 1992PubMedGoogle Scholar
  14. 14.
    Cutler AF, Schubert TT: Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 88:505-509, 1993PubMedGoogle Scholar
  15. 15.
    Labenz J, Leverkus F, Borsch G: Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 29:1070-1075, 1994PubMedGoogle Scholar
  16. 16.
    Sipponen P, Kekki M, Seppala K, Siurala M: The relationship between chronic gastritis and gastric acid secretion. Aliment Pharmacol Ther 10(suppl 1):103-118, 1996PubMedGoogle Scholar
  17. 17.
    Tray G, Marks IN, Louw JA, Jaskiewicz K, Sipponen P, Novis BH, Bank S, Tigler-Wybrandi NA: Changes in acid secretion over the years. A 30-year longitudinal study. J Clin Gastroenterol 25:499-502, 1997PubMedGoogle Scholar
  18. 18.
    Aukee S: Gastritis and acid secretion in patients with gastric ulcers and duodenal ulcers. Scand J Gastroenterol 7:567-574, 1972PubMedGoogle Scholar
  19. 19.
    El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, Williams C, Ardill JES, McColl KEL: Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113:15-24, 1997PubMedGoogle Scholar
  20. 20.
    Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr: Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 8:888-889, 1989PubMedGoogle Scholar
  21. 21.
    Wyatt JI, Rathbone BJ: Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol 23(suppl 142):44-49, 1988Google Scholar
  22. 22.
    Zerbib F, Vialette G, Cayla R, Rudell A, Sauvet P, Bechade D, Seurat P, Lamouliatte H: Les gastritis foliculaires de l'adulte. Relations avec Helicobacter pylori, aspects histologiques et endoscopiques. Gastroenterol Clin Biol 17:529-534, 1993PubMedGoogle Scholar
  23. 23.
    Ladas SD, Rokkas T, Georgopoulos S, Kitsanta P, Liatsos C, Eustathiadou P, Karameris A, Spiliadi C, Raptis SA: Predictive factors and prevalence of follicular gastritis in adults with peptic ulcer and nonulcer dyspepsia. Dig Dis Sci 44:1156-1160, 1999PubMedGoogle Scholar
  24. 24.
    Genta RM, Hamner HW: The significance of lymphoid follicles in the interpretation of gastric biopsy specimens. Arch Pathol Lab Med 118:740-743, 1994PubMedGoogle Scholar
  25. 25.
    Tursi A, Cammarota G, Papa A, Cuoco L, Fedeli G, Gasbarrini G: Long-term follow-up of disappearance of gastric mucosa-associated lymphoid tissue after anti-Helicobacter pylori therapy. Am J Gastroenterol 92:1849-1852, 1997PubMedGoogle Scholar
  26. 26.
    Azuma T, Konishi J, Tanaka Y, Hirai M, Ito S, Kato T, Kohli Y: Contribution of HLA-DQA gene to host's response against Helicobacter pylori. Lancet 343:542-543, 1994Google Scholar
  27. 27.
    Carlson SJ, Yokoo H, Vanagunas A: Progression of gastritis to monoclonal B-cell lymphoma with resolution and recurrence following eradication of Helicobacter pylori. JAMA 275:937-939, 1996PubMedGoogle Scholar
  28. 28.
    Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, Biondi A, Cavalli F: Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 338:804-810, 1998PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 2000

Authors and Affiliations

  • Sotirios D. Georgopoulos
    • 1
    • 2
    • 3
    • 4
  • Spiros D. Ladas
    • 1
    • 2
    • 3
    • 4
  • Stylianos Karatapanis
    • 1
    • 2
    • 3
    • 4
  • Andreas Mentis
    • 1
    • 2
    • 3
    • 4
  • Charis Spiliadi
    • 1
    • 2
    • 3
    • 4
  • Vasilios Artikis
    • 1
    • 2
    • 3
    • 4
  • Sotirios A. Raptis
    • 1
    • 2
    • 3
    • 4
  1. 1.Gastroenterology Unit, Second Department of Internal MedicineAthens University, Evangelismos HospitalAthensGreece
  2. 2.Second Department of Internal MedicineElpis General HospitalAthensGreece
  3. 3.Department of MicrobiologyHellenic Pasteur InstituteAthensGreece
  4. 4.Department of PathologyEvangelismos HospitalAthensGreece

Personalised recommendations